Status:
TERMINATED
Long Term Open Follow-up With H376/95 vs. Warfarin
Lead Sponsor:
AstraZeneca
Conditions:
Stroke Prevention in Patients With Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.
Eligibility Criteria
Inclusion
- Signed informed consent.
- Completion of the study SH-TPA-0002, history of chronic atrial fibrillation (i.e. rapidly beating heart), at least one risk factor for stroke (e.g. high blood pressure, age over 65, previous stroke or similar attack, diabetes or coronary heart disease)
Exclusion
- Conditions associated with increased risk of bleeding, renal impairment, known active liver disease or liver insufficiency
Key Trial Info
Start Date :
August 1 1999
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00206063
Start Date
August 1 1999
End Date
April 1 2006
Last Update
November 15 2010
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Palo Alto, California, United States
2
Research Site
Oostduinkerke, Belgium
3
Research Site
Helsingor, Czechia
4
Research Site
Most, Czechia